Drug Type Small molecule drug |
Synonyms BI 1569912 |
Target |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists), NMDA receptor modulators(Glutamate [NMDA] receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder | Phase 2 | US | 27 Mar 2024 | |
Depressive Disorder | Phase 2 | JP | 27 Mar 2024 | |
Depressive Disorder | Phase 2 | BE | 27 Mar 2024 | |
Depressive Disorder | Phase 2 | BG | 27 Mar 2024 | |
Depressive Disorder | Phase 2 | CZ | 27 Mar 2024 | |
Depressive Disorder | Phase 2 | DE | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | US | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | CN | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | JP | 27 Mar 2024 | |
Depressive Disorder, Major | Phase 2 | BE | 27 Mar 2024 |